. 2013 Aug 8;8(8):e70954. doi: 10.1371/journal.pone.0070954

Table 2. Analysis of CNS mononuclear cell subsets at onset of peak EAE (day 19).

Genotype	Treatment	%CD4 (±SEM)	%CD8 (±SEM)	%CD11b (± SEM)	%CD19 (± SEM)	sIgG Subsets
						CD19^hi sIgG^hi	CD19^intsIgG^int
EVA^−/−	anti-HEL	29.2±2.6	7.5±1.0	28.5±3.9^*	5.8±0.9	7.0±1.0	10.7±1.7
	anti-VLA4	26.0±2.9	5.5±1.3	27.4±5.8	5.7±0.2	5.7±0.3	11.8±1.7
EVA^+/+	anti-HEL	31.5±1.9^*	5.9±0.8	42.6±1.8^*	4.9±1.1	8.4±0.3	2.0±0.4^*
	anti-VLA4	10.4±2.2^*	6.5±1.0	33.7±1.3	3.2±0.4	2.5±0.2^*	2.0±0.6^*

*P<0.01, *P<0.05, *P<0.01 (EVA^+/+ anti-HEL vs anti-VLA4) (as compared to EVA^−/−).

Total mononuclear cells counts per spinal cord were 73,143±8951 (EVA^−/− anti-HEL); 62,102±4008 (EVA^−/− anti-VLA4); 63,732±7504* (EVA^+/+ anti-HEL); 17,540±2717* (EVA^+/+ anti-VLA4).

P<0.01 (EVA^+/+ anti-HEL vs EVA^+/+ anti-VLA4).

Data were generated from using multiple animals (3–7) from multiple independent experiments (3–4).